Stoic ScienceIndustry Insights
Short, practical notes on radiopharmaceutical QC, GxP documentation and the industry news that affects them.
-
The Part 212 rewrite missed its target date again
The Food and Drug Administration's Part 212 rewrite was due as a proposed rule in 09/2026 and hasn't appeared. What it would change, and what labs can check.
Read more →
New posts weekly. Follow in your feed reader: RSS feed.